Fig. 2From: Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trialsRelative risks (RRs) of all malignancies in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKi) and methotrexate (MTX) compared with MTX alone in randomised controlled trials (RCTs) using the Mantel–Haenszel (M–H) random-effect methodBack to article page